Ponatinib is approved to target BCR-ABL in chronic myelogenous leukemia (CML), but is also a type II FLT3 inhibitor with activity against F691L (112). This evidence concerns the gene BCR and chronic myelogenous leukemia, BCR-ABL1 positive.